Waxman/Hatch Changes Likely To Be On House Commerce Cmte. Agenda
Reforming the Hatch/Waxman Act could be added to the Energy & Commerce Committee's 2005 hearing agenda, Chairman Joe Barton (R-Tex.) suggested at a May 18 hearing before the Health Subcommittee
You may also be interested in...
Generic companies are likely to face an increased threat of patent infringement lawsuits on the eve of launch following an appeals court ruling on the standards for seeking a declaratory judgment of noninfringement
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials